Beam Therapeutics (BEAM) Research & Development (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Research & Development data on file, last reported at $104.5 million in Q1 2026.

• Research & Development for Q1 2026 came in at $104.5 million, up 5.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $415.3 million (up 8.85% YoY), and the FY2025 annual result was $409.6 million, up 11.44% from the prior year.
• Research & Development climbed to $104.5 million in Q1 2026 per BEAM's latest filing, from $99.3 million in the prior quarter.
• Over five years, Research & Development peaked at $140.1 million in Q4 2023 and troughed at $65.4 million in Q1 2022.
• A 5-year average of $95.9 million and a median of $98.8 million in 2025 frame the typical range for Research & Development.
• On a YoY basis, Research & Development climbed as much as 63.58% in 2022 and fell as far as 65.59% in 2022.
• A 5-year view of Research & Development shows it stood at $86.3 million in 2022, then surged by 62.24% to $140.1 million in 2023, then slipped by 27.58% to $101.4 million in 2024, then retreated by 2.14% to $99.3 million in 2025, then advanced by 5.29% to $104.5 million in 2026.
• Business Quant data shows BEAM's Research & Development at $104.5 million in Q1 2026, $99.3 million in Q4 2025, and $109.8 million in Q3 2025.